⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VOR News
Vor Biopharma Inc. Common Stock
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
globenewswire.com
VOR
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
globenewswire.com
VOR
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VOR
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
globenewswire.com
VOR
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting USA - English APAC - English APAC - Traditional Chinese
prnewswire.com
VOR